First-Line Treatment of HER2-Positive MBC With Dual Blockade Including Biosimilar Trastuzumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
First-Line Treatment of HER2-Positive Metastatic Breast Cancer With Dual Blockade Including Biosimilar Trastuzumab (SB3): Population-Based Real-World Data From the DBCG
Breast Cancer (Auckl) 2022 Apr 01;16(2022)11782234221086992, A Celik, T Berg, LB Nielsen, MB Jensen, B Ejlertsen, A Knoop, M AnderssonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.